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RESEARCH LETTER
Association of Baclofen With Falls and
Fractures in Patients With CKD
To the Editor:

Baclofen is a popular muscle relaxant that is eliminated
primarily unchanged in the urine.1 We recently reported a
higher risk of encephalopathy in a cohort of 15,942 older
adults with chronic kidney disease (CKD) who started
baclofen at ≥20 versus <20 mg/d; a higher risk was also
observed in all baclofen users versus nonusers.2 In another
study of patients receiving dialysis, 1 in 14 were hospitalized with encephalopathy within 3 days of starting
baclofen.3

In the present study, we analyzed the same cohort of
15,942 older adults with CKD not receiving dialysis,2 and
examined the 30-day risk of a hospital encounter with a
fall, a fracture, or hypotension in patients newly prescribed
baclofen at ≥20 versus <20 mg/d. The data source, design,
and methods were the same as in our prior report2 and are
described in Table S1.
Briefly, we analyzed linked administrative health care
data housed at ICES in Ontario, Canada, where all residents
aged ≥65 years have universal prescription drug coverage.
The primary cohort included adults aged ≥66 (to ensure at
least 1 year of drug coverage) who had an estimated
glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2
and who were newly dispensed oral baclofen from an
outpatient pharmacy between January 1, 2007, and March
1, 2018. Patients with evidence of baclofen use in the 180day period before the prescription start date were excluded
(this period was extended to 5 years in a sensitivity
analysis).
The primary exposure was baclofen ≥ 20 mg/
d (20 mg/d is the median dose reported in cases of baclofen toxicity, and the median dose prescribed during the
study period [Table S2]).2 To reduce the potential for
indication bias, the prespecified reference group was
baclofen < 20 mg/d.
In a secondary analysis, study outcomes in each group
of baclofen users (≥20 and <20 mg/d) were compared
separately to nonusers (ie, patients with CKD not taking
baclofen). Nonusers were randomly assigned a simulated
baclofen start date that followed the same distribution of
start dates as baclofen users.
Inverse probability of treatment weighting on the propensity score was used to balance comparison groups on
164 indicators of baseline health, including indications for

Table 1. Baseline Characteristics of Older Adults With CKD Newly Prescribed Baclofen in Ontario, Canada (2007-2018)
Observed Data (N = 15,942)

Weighted Data (N = 19,387)a

Baclofen Dose

Demographics
Women
Men
Age, y
Residence
Urban
Rural
Long-term care
Income quintilec
1 (lowest)
2
3 (middle)
4
5 (highest)

Baclofen Dose

≥20 mg/d
(n = 9,707)

<20 mg/d
(n = 6,235)

≥20 mg/d
(n = 9,707)

<20 mg/d
(n = 9,680)

Std
Diffb

5,719 (58.9%)
3,988 (41.1%)
76.5 ± 6.9

3,980 (63.8%) 10%
2,255 (36.2%) 10%
78.0 ± 7.4
21%

5,719 (58.9%)
3,988 (41.1%)
76.5 ± 6.9

5,702 (58.9%)
3,978 (41.1%)
76.5 ± 8.8

2%
0%
0%

8,870 (91.4%)
837 (8.6%)
210 (2.2%)

5,800 (93.0%) 6%
435 (7.0%)
6%
379 (6.1%)
20%

8,870 (91.4%)
837 (8.6%)
210 (2.2%)

8,845 (91.4%)
835 (8.6%)
217 (2.2%)

0%
0%
0%

2,313 (23.8%)
2,098 (21.6%)
2,010 (20.7%)
1,893 (19.5%)
1,393 (14.4%)

1,508 (24.2%)
1,345 (21.6%)
1,280 (20.5%)
1,145 (18.4%)
957 (15.3%)

2,313 (23.8%)
2,098 (21.6%)
2,010 (20.7%)
1,893 (19.5%)
1,393 (14.4%)

2,309 (23.9%)
2,121 (21.9%)
1,988 (20.5%)
1,871 (19.3%)
1,389 (14.4%)

0%
1%
0%
1%
0%

Std Diffb

1%
0%
0%
3%
3%

(Continued)
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Table 1 (Cont'd). Baseline Characteristics of Older Adults With CKD Newly Prescribed Baclofen in Ontario, Canada (2007-2018)

Kidney function
eGFR, mL/min/1.73 m2d
eGFR category
45-<60 mL/min/1.73 m2
30-<45 mL/min/1.73 m2
<30 mL/min/1.73 m2
Baclofen prescriber
General practitioner
Other
Missing
Comorbiditiesf
Anemia
Parkinson disease
Prior hypotension
Rheumatoid arthritis
Syncope
Ischemic stroke
Encephalopathy
Prior falls
Prior fractures
Hemorrhagic stroke
Acute urinary retention
Health care visits and testse
Primary care visits
Emergency department visits
Serum creatinine tests
Medication usef
Selective serotonin reuptake inhibitors
Benzodiazepines
Antipsychotics
Opioids
Anticonvulsants

Observed Data (N = 15,942)

Weighted Data (N = 19,387)a

Baclofen Dose

Baclofen Dose

≥20 mg/d
(n = 9,707)

<20 mg/d
(n = 6,235)

≥20 mg/d
Std Diffb (n = 9,707)

<20 mg/d
(n = 9,680)

Std
Diffb

47.5 ± 10.1

47.3 ± 10.2

2%

47.5 ± 10.1

47.5 ± 12.6

0%

6,404 (66.0%)
2,616 (26.9%)
687 (7.1%)

4,085 (65.5%) 1%
1,682 (27.0%) 0%
468 (7.5%)
2%

6,404 (66.0%)
2,616 (26.9%)
687 (7.1%)

6,388 (66.0%)
2,580 (26.7%)
711 (7.4%)

0%
0%
1%

8,433 (86.9%)
665 (6.9%)
609 (6.3%)

5,208 (83.5%) 1%
533 (8.5%)
6%
494 (7.9%)
6%

8,433 (86.9%)
665 (6.9%)
609 (6.3%)

8,399 (86.8%)
669 (6.9%)
611 (6.3%)

0%
0%
0%

2,667 (27.5%)
197 (2.0%)
190 (2.0%)
636 (6.6%)
168 (1.7%)
191 (2.0%)
352 (3.6%)
371 (3.8%)
627 (6.5%)
28 (0.3%)
210 (2.2%)

1,719 (27.6%)
174 (2.8%)
125 (2.0%)
415 (6.7%)
112 (1.8%)
171 (2.7%)
305 (4.9%)
295 (4.7%)
458 (7.3%)
24 (0.4%)
161 (2.6%)

0%
5%
0%
0%
1%
5%
6%
4%
3%
2%
3%

2,667 (27.5%)
197 (2.0%)
190 (2.0%)
636 (6.6%)
168 (1.7%)
191 (2.0%)
352 (3.6%)
371 (3.8%)
627 (6.5%)
28 (0.3%)
210 (2.2%)

2,548 (26.3%)
198 (2.0%)
190 (2.0%)
640 (6.6%)
163 (1.7%)
195 (2.0%)
346 (3.6%)
366 (3.8%)
627 (6.5%)
30 (0.3%)
199 (2.1%)

3%
0%
0%
0%
0%
0%
0%
0%
0%
0%
1%

11.2 ± 9.6
0.7 ± 1.4
2.6 ± 2.2)

11.8 ± 10.2
0.7 ± 1.4
2.7 ± 2.3

6%
4%
0%

11.2 ± 9.6
0.7 ± 1.4
2.6 ± 2.2

11.2 ± 11.4
0.7 ± 1.9
2.6 ± 2.9

0%
1%
0%

991 (10.2%)
1,897 (19.5%)
376 (3.9%)
2,749 (28.3%)
435 (4.5%)

750 (12.0%)
1,152 (18.5%)
284 (4.6%)
1,594 (25.6%)
261 (4.2%)

6%
3%
3%
6%
1%

991 (10.2%)
1,897 (19.5%)
376 (3.9%)
2,749 (28.3%)
435 (4.5%)

994 (10.3%)
1,885 (19.5%)
378 (3.9%)
2,734 (28.2%)
451 (4.7%)

0%
0%
0%
0%
1%

Unless otherwise speciﬁed, baseline characteristics were assessed on the date the patient ﬁlled the baclofen prescription. Values given as count (percentage) or
mean ± SD.
a
Weighted using inverse probability of exposure weighting based on propensity scores. The propensity score was estimated using multivariable logistic regression with
164 covariates chosen a priori.2 Probabilities of treatment were determined separately for the primary and secondary analyses. Patients in the reference groups received a
weight of [propensity score / (1 – propensity score)] and those in the exposed groups a weight of 1 (Table S1).4-6 This method produces a weighted pseudosample of
patients in the reference group with the same distribution of measured covariates as the exposure group.4,5
b
Standardized difference: difference between the groups divided by the pooled SD; a value greater than 10% is interpreted as a meaningful difference.
c
Based on average neighborhood income on the index date. Missing data on income quintile (0.3%) were recorded as the middle quintile.
d
The most recent eGFR in the 7-365 days before the index date; eGFR calculated by CKD-EPI equation (Table S1); information on race was not available and all patients
were assumed not to be of African-Canadian race (African-Canadians represented <5% of Ontario population in 2006).
e
Baseline comorbidities were assessed in the 5-year (comorbidities) or 1-year (total visits or tests) period before the prescription start date.
f
Medication use examined in the 120-day period before the prescription start date (the Ontario Drug Beneﬁt program dispenses a maximum 100-day supply).

baclofen use.4-6 Weighting methods are described in notes
to Table 1 and in Table S1.4-6 Weighted risk ratios (wRR)
were obtained using modified Poisson regression,7 and
weighted risk differences (wRD) using a binomial
regression model with an identity link function. A prespecified subgroup analysis by baseline eGFR (in 3 categories) was conducted for the most common outcome
(hospitalization with a fall).
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The primary analysis included 15,942 patients.
Weighting resulted in 2 well-balanced groups (Table S3);
selected characteristics are shown in Table 1. The majority
of prescribing physicians were primary care physicians
(86%); <1% were nephrologists (Table 1). Less than 5% of
patients received the recommended starting dose of 7.5 or
5.5 mg/d (Tables S4 and S5). Starting baclofen at ≥20
versus <20 mg/d was associated with a higher risk of
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Table 2. Risk of a Fall, Fracture, and Hypotension in Older Adults With CKD Newly Prescribed Baclofen at ≥20 Versus <20 mg/d
Outcome:
Hospital
Encounter
With
Fallb
Fractured
Hypotensione

Weighteda No. of
Observed No. of Patients, Patients, by Baclofen
by Baclofen Dose
Dose

Number
Needed
to Harm
Risk Ratio
(95% CI)
(95% CI)
278 (143-3333)c 1.38 (1.01-1.90)

≥20 mg/d
<20 mg/d ≥20 mg/d
<20 mg/d Risk Difference
(n = 9,707)
(n = 6,235) (n = 9,707)
(n = 9,680) (95% CI)
127 (1.31%) 65 (1.04%) 127 (1.31%) 92 (0.94%) 0.36%
(0.03% to 0.70%)
36 (0.37%)
20 (0.32%) 36 (0.37%)
29 (0.30%) 0.07%
Not
(–0.12% to 0.26%) available
32 (0.33%) 6 (0.10%)
32 (0.33%) 10 (0.11%) 0.22%
456 (270-1250)f
(0.08% to 0.37%)

1.23 (0.70-2.19)
3.06 (1.26-7.47)

Reference group: Baclofen dose < 20 mg/d.
a
Inverse probability of treatment weighting on the propensity score was used to balance comparison groups on indicators of baseline health4-6; further details in Table 1
and Table S1. Weighted risk ratios were obtained using modiﬁed Poisson regression7; weighted risk differences, by using a binomial regression model with an identity link
function.
b
Patient seen in the emergency department or admitted to the hospital with a fall diagnosis (ICD-10 code W00-W19).
c
For every 278 patients prescribed baclofen at ≥20 vs <20 mg/d in the outpatient setting, 1 patient was hospitalized or visited an emergency department with a fall within
30 days of starting baclofen.
d
Includes major fractures of hip (ICD-10 code S720, S721; S722. Canadian Classiﬁcation of Health Interventions [CCI] code 1VA73, 1VC73, 1VA74, 1VA53, 1VC74,
1VA80), pelvis (ICD-10 code S321, S322, S324, S323, S325, S327, S328), humerus (ICD-10 code S422), and radius (ICD-10 code S52; CCI code 1TV73, 1TV74,
1TV03; Ontario Health Insurance Program [OHIP] code F014, F022, F023, F025, F026, F028, F030, F032, F033, F046, F024, F027, F031, Z203).
e
Patient seen in the emergency department or admitted to the hospital with a hypotension diagnosis (ICD-10 code I95).
f
For every 456 patients prescribed baclofen at ≥20 vs <20 mg/d in the outpatient setting, 1 patient was hospitalized or visited an emergency department with hypotension
within 30 days of starting baclofen.

hospitalization with a fall (wRR, 1.38 [95% CI, 1.011.90]; wRD, 0.36% [95% CI, 0.03%-0.70%]) and hypotension (wRR, 3.06 [95% CI, 1.26-7.47]; wRD, 0.22%
[95% CI, 0.08%-0.37%]), but not fracture (wRR, 1.23
[95% CI, 0.70-2.19]; wRD, 0.07% [95% CI, –0.12% to
0.26%]) (Table 2). Results were consistent in 2 sensitivity
analyses (Tables S6 and S7). The association with falls was
not significantly modified by baseline eGFR (Fig S1),
acknowledging there was limited statistical power to detect
it if it exists.
The secondary analysis included 15,942 baclofen
users and 284,263 nonusers; characteristics of high-dose
baclofen users versus nonusers and low-dose users
versus nonusers are in Tables S8 and S9, respectively.
Compared with nonusers, high-dose users had a higher
risk of hospitalization with a fall, fracture, and hypotension; low-dose users had a higher risk of hospitalization with a fall, but not fracture or hypotension
(Table S10).
In summary, older adults with CKD starting baclofen
at ≥20 versus <20 mg/d were at higher risk for hospitalization with a fall and hypotension; for every 278
patients prescribed baclofen at ≥20 versus <20 mg/d, 1
was hospitalized with a fall. Although comparison
groups were well balanced, residual confounding is still
possible, and we did not account for dose changes in
other medications such as opioids or benzodiazepines,
which could influence study outcomes. Nonetheless,
taken together the results of this study and others
suggest that baclofen should be used with caution in
older adults with CKD, and only at low doses.2,3 To
better protect patients with CKD, the product
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monograph should contain clear dose recommendations
based on kidney function,1 and computerized
medication-order entry warnings with dosing prompts
are also recommended.8,9
Flory T. Muanda, MD, PhD, Peter G. Blake, MB, FRCPC,
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Chauvin, BSc, Stephanie N. Dixon, PhD, Eric
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